Clinical

Body surface area offers a simple starting point for gauging vitiligo severity, but the panel argues that phenotype markers, anatomic location, and disease activity carry more weight in shaping treatment urgency than surface area alone.

In this episode titled, 'Practical Disease Activity Scoring for Rheumatoid Arthritis Follow-Up Visits', Dr. Julia Buchfuhrer led the conversation about the following questions: • Let's start with how you're assessing disease activity in RA patients in routine practice. Which scoring tools are you using most consistently, and how are you building reassessment into the care cycle? • How frequently are you bringing patients back to formally reevaluate disease activity after a treatment change and what is your clinical rationale for this decision?

This segment explores the evolving role of oral selective estrogen receptor degraders in early-stage hormone receptor–positive, HER2-negative breast cancer and their potential impact on treatment paradigms.

Noureddin outlined the striking epidemiological burden of MASLD and MASH in patients with obesity, with prevalence climbing dramatically with increasing BMI, reaching up to 90% in patients with a BMI of 40 or higher, and affecting approximately 60% of individuals with type 2 diabetes.

Vitiligo's clinical course splits into segmental and non-segmental presentations, each carrying a distinct prognosis. Dr. Rosmarin explains how disease activity, not just extent, determines whether a patient needs urgent intervention or watchful monitoring.

In this episode, 'Traditional Pharmacologic Therapies for Alzheimer's Disease Agitation: Mechanisms, Evidence, and Adverse Events,' the expert neurologists explored the following questions: What are the traditional therapies such as antipsychotics used in the management of patients with Alzheimer's disease agitation and their respective mechanisms of action? What has the data demonstrated with these therapies? What are the adverse events seen with these therapies? When are you utilizing dose reductions with these therapies?

In 'Non-Pharmacologic Approaches to Alzheimer's Disease Agitation: Interventions, Best Practices, and Case Examples,' the expert neurologists examined the following critical questions: Before we get into the medications used to treat Alzheimer's disease agitation, what are the non-pharmacologic options and their respective roles? What are best practices for educating patients and caregivers on these and some case examples?

An FDA committee voted 9-3 that available data did not provide substantial evidence of effectiveness for deramiocel in DMD.

MASLD/MASH was associated with higher mild cognitive impairment risk and lower dementia odds, but competing risks may explain the latter finding.

Nitipong Permpalung, MD, MPH, discusses how early remdesivir may reduce graft loss and cardiovascular events after COVID-19 in kidney transplant recipients.

These findings reinforce that matching therapy intensity and type to genetic and treatment-history profile is likely to be the next lever for improving outcomes.

Led by the moderator, Christina Poh shared her closing reflections on the relapsed or refractory follicular lymphoma treatment landscape, expressing strong optimism about both the current state and near-term future of the field, noting that the development of many novel, highly effective treatment options over the past several years has fundamentally transformed what is possible for patients with this chronic, relapsing disease.

Christina Poh described the real-world data from eight CUBIC centers as highly encouraging, interpreting response rates that match or exceed those seen in pivotal trials in a heavily pretreated and older patient population as confirmation that bispecific antibodies are a broadly active and impressive class of treatment that already plays an important role in relapsed or refractory follicular lymphoma.

Experts discuss barriers to eating disorder diagnosis and treatment for BIPOC patients and strategies to improve equitable care.

A study found that elevated IL-6 and IL-17A levels were associated with greater fatigue for up to 3 years after CRC diagnosis.

The FDA's push for faster, more diverse trials misses the real fix: experts say AI simulation and readability, not red tape, close the gap.

HIV disrupts several steps required for durable antibody production; for example, CD4+ helper T cells are depleted and functionally impaired.

Acoramidis attenuated declines in patient-reported health status through 30 months, complementing previously reported survival and hospitalization benefits.

The meta-analysis of 17 studies found that frailty was strongly associated with cognitive impairment in CKD, highlighting the need for further research to determine a causal relationship.

Oral zasocitinib delivered skin clearance once limited to injectable biologics in phase 3 psoriasis trials, including hard-to-treat sites.

Early remdesivir treatment was associated with lower graft loss and cardiovascular events in kidney transplant recipients, noted Nitipong Permpalung, MD, MPH.

A recent study found semaglutide more than doubled the likelihood of MASH resolution, but it did not significantly improve fibrosis.

A new review argues that bulevirtide is unlikely to succeed as a stand-alone treatment and calls for combination regimens that restore antiviral immunity.

New cancer drugs reached patients fastest, but overall access timelines remained lengthy across the US, France, Germany, and Switzerland.

East Asian patients with generalized myasthenia gravis (gMG) saw meaningful nipocalimab benefits in a Vivacity-MG3 subgroup analysis.